These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 26562543)

  • 1. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
    Maqbool M; Mobashir M; Hoda N
    Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.
    Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A
    Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK-3 inhibitors for Alzheimer's disease.
    Avila J; Hernández F
    Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
    Khan I; Tantray MA; Alam MS; Hamid H
    Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
    Liu SN; Shen ZF
    Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation.
    Bustanji Y; Taha MO; Almasri IM; Al-Ghussein MA; Mohammad MK; Alkhatib HS
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):771-8. PubMed ID: 18720192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
    Medina M; Avila J
    Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease.
    Noh MY; Chun K; Kang BY; Kim H; Park JS; Lee HC; Kim YH; Ku S; Kim SH
    Biochem Biophys Res Commun; 2013 May; 435(2):274-81. PubMed ID: 23632329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithium, a potential protective drug in Alzheimer's disease.
    Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J
    Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.
    Huang HC; Klein PS
    Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
    Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
    J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future.
    Maqbool M; Hoda N
    Curr Pharm Des; 2017 Nov; 23(29):4332-4350. PubMed ID: 28714403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [GSK-3beta: a central kinase for neurodegenerative diseases?].
    Petit-Paitel A
    Med Sci (Paris); 2010 May; 26(5):516-21. PubMed ID: 20510151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate competitive GSK-3 inhibitors - strategy and implications.
    Eldar-Finkelman H; Licht-Murava A; Pietrokovski S; Eisenstein M
    Biochim Biophys Acta; 2010 Mar; 1804(3):598-603. PubMed ID: 19770076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
    Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M
    Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.